...
首页> 外文期刊>臨床血液 >Infection control for the treatment of hematological malignancies: a survey of the Kyushu Hematology Organization for Treatment Study Group (K-HOT)
【24h】

Infection control for the treatment of hematological malignancies: a survey of the Kyushu Hematology Organization for Treatment Study Group (K-HOT)

机译:感染控制用于血液系统恶性肿瘤的治疗:九州血液学治疗组织研究组(K-HOT)的调查

获取原文
获取原文并翻译 | 示例

摘要

The Kyushu Hematology Organization for Treatment Study Group (K-HOT) consisted of 22 institutions specializing in hematology in Kyushu. This study is aimed at reviewing the daily practice of infection control for the treatment of hematological malignancies in our group. Nominal questionnaires were mailed to the hematology department in each institution from November 2001 to April 2002. For the first general surveys, 19 of 22 (86%) institutions responded. The second survey was mailed to the 19 respondents and 17 answered the detailed questionnaires with a response rate of 89%. Prophylactic use of trimethoprim-sulfamethoxazole (ST) against Pneumocystis carinii and anti-mycobacterial drugs in patients who had a history of tuberculosis was routine especially for patients with adult T-cell leukemia/lymphoma (ATL). Furthermore, the neutrophil counts to start a granulocyte-colony stimulating factor appeared to be high in ATL as compared with other hematological malignancies. In the setting of autologous stem cell transplantation (SCT), prophylactic use of acyclovir, immunoglobulin and ST was not routine and was reduced in duration, if used at all, as compared with allogeneic SCT. For allogeneic SCT, the cumulative dose of immunoglobulin significantly varied from institutions to institutions. The benefit of this study is the ability to recognize practical management patterns for infection control.
机译:九州血液学治疗研究组织(K-HOT)由九州的22个血液学专业机构组成。这项研究的目的是回顾我们小组中感染控制的日常实践,以治疗血液系统恶性肿瘤。从2001年11月至2002年4月,将名义上的调查表邮寄到每个机构的血液学部门。对于首次普查,22家机构中有19家(86%)做出了回应。第二次调查邮寄给了19位受访者,其中17位回答了详细问卷,答复率为89%。在有结核病史的患者中,预防性使用甲氧苄啶-磺胺甲基异恶唑(ST)对抗卡氏肺孢子虫和抗分枝杆菌药物是常规的,尤其是对于成人T细胞白血病/淋巴瘤(ATL)患者。此外,与其他血液系统恶性肿瘤相比,ATL中启动粒细胞集落刺激因子的嗜中性粒细胞计数似乎较高。在自体干细胞移植(SCT)的情况下,与同种异体SCT相比,阿昔洛韦,免疫球蛋白和ST的预防性使用不是常规方法,并且如果完全使用,则可减少持续时间。对于同种异体SCT,不同机构间免疫球蛋白的累积剂量差异很大。这项研究的好处是能够识别感染控制的实际管理模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号